Immunophenotype based on inflammatory cells, PD-1/PD-L1 signalling pathway and M2 macrophages predicts survival in gastric cancer

被引：22

作者：

Junttila, Anna ^{[1
]}

Helminen, Olli ^{[1
]}

Vayrynen, Juha P. ^{[2
,3
,4
,5
,6
]}

Ahtiainen, Maarit ^{[7
]}

Kenessey, Istvan ^{[8
,9
]}

Jalkanen, Sirpa ^{[8
,9
]}

Mecklin, Jukka-Pekka ^{[10
,11
]}

Kellokumpu, Ilmo ^{[1
]}

Kuopio, Teijo ^{[7
,12
,13
]}

Bohm, Jan ^{[12
]}

Mrena, Johanna ^{[1
]}

机构：

[1] Cent Finland Cent Hosp, Dept Surg, Jyvaskyla, Finland

[2] Univ Oulu, Canc & Translat Med Res Unit, Med Res Ctr Oulu, Oulu, Finland

[3] Oulu Univ Hosp, Oulu, Finland

[4] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[5] Harvard Med Sch, Boston, MA 02115 USA

[6] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA

[7] Cent Finland Hlth Care Dist, Dept Educ & Res, Jyvaskyla, Finland

[8] Univ Turku, MediCity Res Lab, Turku, Finland

[9] Univ Turku, Inst Biomed, Turku, Finland

[10] Univ Jyvaskyla, Dept Educ & Res, Cent Finland Cent Hosp, Jyvaskyla, Finland

[11] Univ Jyvaskyla, Sport & Hlth Sci, Jyvaskyla, Finland

[12] Cent Finland Cent Hosp, Dept Pathol, Jyvaskyla, Finland

[13] Univ Jyvaskyla, Dept Biol & Environm Sci, Jyvaskyla, Finland

来源：

BRITISH JOURNAL OF CANCER | 2020年 / 123卷 / 11期

关键词：

TUMOR-ASSOCIATED MACROPHAGES; MICROSATELLITE INSTABILITY; PROGNOSTIC-SIGNIFICANCE; PD-L1; METAANALYSIS;

D O I：

10.1038/s41416-020-01053-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background Immune response against cancer has prognostic impact but its role in gastric cancer is poorly known. The aim of the study was to assess the prognostic significance of immune cell score (CD3+, CD8+), tumour immune escape (PD-L1, PD-1) and immune tolerance (Clever-1). Methods After exclusion of Epstein-Barr virus positive (n = 4) and microsatellite instable (n = 6) tumours, the study included 122 patients with GC undergoing D2 gastrectomy. CD3+ and CD8+ based ICS, PD-L1, PD-1 and Clever-1 expressions were evaluated. Differences in survival were examined using Cox regression adjusted for confounders. The primary outcome was 5-year survival. Results The 5-year overall survival rate was 43.4%. High ICS was associated with improved overall survival (adjusted HR 0.48 (95% CI 0.26-0.87)) compared to low ICS. In the high ICS group, patients with PD-L1 expression (5-year survival 69.2 vs. 53.1%,p = 0.317), high PD-1 (5-year survival 70.6 vs. 55.3%p = 0.312) and high Clever-1 (5-year survival 72.0% vs. 45.5% (p = 0.070) had poor prognosis. Conclusions High ICS was associated with improved survival. In the high ICS group, patients with high PD-L1, PD-1 and Clever-1 had poor prognosis highlighting the importance of immune escape and immune tolerance in GC.

引用

页码：1625 / 1632

页数：8

共 50 条

[21] Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer [J].

Cheng, Chao ;

Zhuge, Lingdun ;

Xiao, Xin ;

Luan, Siyuan ;

Yuan, Yong .

FRONTIERS IN ONCOLOGY, 2022, 12

[22] The roles of PD-1/PD-L1 and its signalling pathway in gastrointestinal tract cancers [J].

Cui, Chunguo ;

Yu, Bo ;

Jiang, Qi ;

Li, Xingfang ;

Shi, Kaiyao ;

Yang, Zecheng .

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2019, 46 (01) :3-10

[23] The PD-1/PD-L1 Pathway in Human Pathology [J].

Saresella, M. ;

Rainone, V. ;

Al-Daghri, N. M. ;

Clerici, M. ;

Trabattoni, D. .

CURRENT MOLECULAR MEDICINE, 2012, 12 (03) :259-267

[24] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer [J].

Monneur, Audrey ;

Goncalves, Anthony ;

Bertucci, Francois .

BULLETIN DU CANCER, 2018, 105 (03) :261-272

[25] PD-1 and PD-L1 inhibitors in oesophago-gastric cancers [J].

Telli, Tugba Akin ;

Bregni, Giacomo ;

Camera, Silvia ;

Deleporte, Amelie ;

Hendlisz, Main ;

Sclafani, Francesco .

CANCER LETTERS, 2020, 469 :142-150

[26] AKT/mTOR Signal Cascade and Expression of PD-1, PD-L1, and PD-L2 in Gastric Cancer [J].

L. V. Spirina ;

A. V. Avgustinovich ;

S. G. Afanas’ev ;

I. V. Kondakova ;

M. Yu. Volkov ;

A. Yu. Dobrodeev ;

A. I. Boronkina .

Bulletin of Experimental Biology and Medicine, 2020, 170 :75-78

[27] AKT/mTOR Signal Cascade and Expression of PD-1, PD-L1, and PD-L2 in Gastric Cancer [J].

Spirina, L. V. ;

Avgustinovich, A. V. ;

Afanas'ev, S. G. ;

Kondakova, I. V. ;

Volkov, M. Yu. ;

Dobrodeev, A. Yu. ;

Boronkina, A. I. .

BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2020, 170 (01) :75-78

[28] PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy [J].

Salmaninejad, Arash ;

Valilou, Saeed Farajzadeh ;

Shabgah, Arezoo Gowhari ;

Aslani, Saeed ;

Alimardani, Malihe ;

Pasdar, Alireza ;

Sahebkar, Amirhossein .

JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (10) :16824-16837

[29] The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy [J].

Wenxiao Jiang ;

Shuya Pan ;

Xin Chen ;

Zhi-wei Wang ;

Xueqiong Zhu .

Molecular Cancer, 20

[30] The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer [J].

Qiao, Xin-wei ;

Jiang, Jian ;

Pang, Xin ;

Huang, Mei-chang ;

Tang, Ya-jie ;

Liang, Xin-hua ;

Tang, Ya-ling .

FRONTIERS IN IMMUNOLOGY, 2020, 11

← 1 2 3 4 5 →